Author: Chong, Vui Heng; Chong, Pui Lin; Metussin, Dhiya; Asli, Rosmonaliza; Momin, Riamiza Natalie; Mani, Babu Ivan; Abdullah, Muhammad Syafiq
Title: Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVIDâ€19 Cord-id: y6cau1q6 Document date: 2020_5_22
ID: y6cau1q6
Snippet: COVID-19 is a contagious disease caused by Severe Adult Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). Currently the role of HCQ in COVID-19 remains controversial but HCQ continued to be used in the absence of any effective therapy. We showed that cardiac conduction abnormalities were common in patients with HCQ added on to lopinavir/ritonavir. After starting HCQ, there were 5 (45.5%) new events of which four (36.3%) were attributed to HCQ: QTc prolongations in 3 patients with additional deve
Document: COVID-19 is a contagious disease caused by Severe Adult Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). Currently the role of HCQ in COVID-19 remains controversial but HCQ continued to be used in the absence of any effective therapy. We showed that cardiac conduction abnormalities were common in patients with HCQ added on to lopinavir/ritonavir. After starting HCQ, there were 5 (45.5%) new events of which four (36.3%) were attributed to HCQ: QTc prolongations in 3 patients with additional development of conduction blocks (fascicular block and right bundle brunch block in one patient respectively) and one patient with bradycardia. All conduction abnormalities settled after discontinuation of HCQ. Therefore monitoring is recommended when considering HCQ in treating patients with COVID-19. This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents- acute renal failure and lymphocyte ratio: 1, 2
- lopinavir ritonavir and lymphocyte ratio: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date